Executive Summary

Xenical® (orlistat) capsules, 120 mg, were approved for obesity management in April 1999. On June 23, 2003, the sponsor submitted this sNDA including two pediatric studies to fulfill the Pediatric Exclusivity Written Request. The two studies are listed as follows:

Protocol PP16203:
The effect of orlistat (Xenical, Ro 18-0647) on the balance of selected minerals in obese pediatric and adolescent patients.

Protocol NM16189:
A double-blind, placebo-controlled, 54-week study of the efficacy and safety of Xenical® (orlistat) in the weight management of obese pediatric patients.

In these studies, plasma concentrations of orlistat and its metabolites M1 and M3 at 2 to 4 hours post lunch dose were measured. In study PP16203, the effects of orlistat on mineral balance (calcium, copper, iron, magnesium, and zinc), plasma and urine sodium and potassium, urine creatinine, and fecal fat excretion were evaluated. Based on the study results, the sponsor proposed labeling changes including the Special Populations and Other Short-term Studies subsections of the CLINICAL PHARMCOLOGY section.

Results showed that the exposure to orlistat and its metabolites M1 and M3 in adolescent patients was similar to historical data in adults at the same dose level. Orlistat did not affect mineral balance of calcium, copper, magnesium, or zinc. Iron balance was decreased in both placebo and orlistat groups and there was more loss in the orlistat treatment group. Orlistat treated patients had increased daily fecal fat excretion (15.9 g/day or 27% dietary intake) relative to placebo-treated patients (4.1 g/day or 7% of dietary intake).

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Hae-Young Ahn

12/9/03 01:55:02 PM